Takeda's Ixazomib Improves PFS in Multiple Myeloma, Interim Analysis Finds

Interim analysis during a phase 3 study of Ixazomib in patients with relapsed or refractory multiple myeloma found that the drug improved the primary endpoint of progression-free survival.

Takeda Pharmaceutical Company Limited today announced that the randomized, double-blind, placebo-controlled TOURMALINE-MM1 pivotal Phase 3 trial evaluating the safety and efficacy of ixazomib, the first oral proteasome inhibitor, conducted in patients with relapsed or refractory multiple myeloma (MM) achieved its primary endpoint of improving progression-free survival at the first pre-specified interim analysis. In the trial, patients treated with investigational ixazomib plus lenalidomide and dexamethasone lived without their disease worsening for a significantly longer time compared to patients who received placebo plus lenalidomide/dexamethasone.

Efficacy and safety data were reviewed by an Independent Data Monitoring Committee (IDMC). Takeda intends to submit these data to health authorities globally for marketing authorizations.

Link to the complete article on MarketWatch: http://on.mktw.net/1Cd5JlY